Asthma is a chronic respiratory disorder canonically associated with type 2 airway
inflammation as characterized by elevated levels of eosinophils, immunoglobulin E, and …

Recent developments in therapeutic strategies have provided alternatives to corticosteroids
as the cornerstone treatment for managing airway inflammation in asthma. The past two …

Introduction: It is recognized that airway inflammation is key to asthma pathogenesis.
Biopharmaceutical approaches have identified new therapies that target key cells and …

Objective The use of biologics in severe asthma has made substantial strides in disease
management and fostered a personalized medicine approach; however, how, when, and …

Over the last 30 years, scientific research into asthma has focused almost exclusively on one
component of the disorder–airway inflammation–as being the key underlying feature. These …

Patients with severe uncontrolled asthma have disproportionally high morbidity and
healthcare utilization as compared with their peers with well-controlled disease. Although …

Asthma is a heterogeneous disease, with the immune processes behind the chronic
inflammation underlying this disorder differing between the various identified asthma …

What is becoming clear in filling the pipeline with new asthma therapies that treat the
underlying disease causes is the need for closer working between clinical academics and …

Objective: Asthma is a common chronic disease with various phenotypes and therapeutic
responses. Unlike other diseases, current anti-inflammatory treatment with corticosteroids …

Despite the availability of a great number of medications, the asthma epidemic is continuing
to increase. It is obvious that a high, unmet medical need remains and innovative …